因“九期一”学术营销违规 绿谷医药被处罚40万元

Core Points - The Shanghai Pudong New District Market Supervision Administration has imposed an administrative penalty of 400,000 RMB on Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. for commercial bribery related to the promotion of the drug "Jiuqi Yi" (Mannitol Capsules) [1][2] - The company engaged in systematic and covert practices to influence doctors' prescription decisions by providing "lecture fees" and hosting banquets, starting from July 2022 until July 2024 [1][2] Summary by Sections Administrative Penalty - Green Valley Pharmaceutical was fined 400,000 RMB for violating the Pharmaceutical Administration Law by providing improper benefits to physicians [2] - The company conducted 587 academic meetings during the two-year period, with total payments amounting to 609,800 RMB for lecture fees and 223,600 RMB for dining expenses [2] Regulatory Findings - The regulatory body found no direct correlation between the payments made and the procurement amounts of "Jiuqi Yi" at the hospitals involved, leading to no recognition of illegal gains [2] - The actions of Green Valley Pharmaceutical were deemed to constitute commercial bribery, violating Article 88 of the Pharmaceutical Administration Law [2] Mitigating Factors - The regulatory authority considered the duration and severity of the violations, but also noted that this was the company's first offense and that it cooperated with the investigation and ceased the illegal payments [2] - The penalty was determined to be lighter due to the company's corrective actions following the incident [2] Operational Changes - In June 2023, Green Valley Pharmaceutical announced the closure of offices and production areas related to Mannitol Capsules, with operations halted as of May 30, 2025, due to the expiration of the drug's registration certificate [3]